IMCCHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores IM Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMCC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Dec 2021 | Roth Capital | Initiates | Buy | — |
| 5 Oct 2021 | Roth Capital | Initiates | Buy | — |
| 10 June 2021 | Alliance Global Partners | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMCC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 99% of US stocks
Cheaper than 96% of US stocks
Cheaper than 70% of US stocks
Higher than 7% of US stocks
Higher than 16% of US stocks
Higher than 16% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IM Cannabis Corp. has a market value of $1.1M and an enterprise value of $9.5M.
Revenue in the twelve months to 31 Mar 2026: $50.9M. The latest quarter shrank 40.2% year on year.
Net income over the same four quarters: −$14.4M, a −28.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: $49K, after $18K of capital spending.
IM Cannabis Corp. spent $0.0 on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: −0.7×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.
IM Cannabis Corp. employs 44 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IM Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IM Cannabis Corp. announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor, according to a Sept. 2, 2026 press release from Toronto and Glil Yam, Israel.
Why it matters — IMCC watchers would care because this new financing provides the company with additional capital.
IM Cannabis Corp. announced that its common shares began trading on the Nasdaq Capital Market on a 30:1 post-consolidated basis, effective August 27, 2026. The company's existing trading symbol "IMCC" remains unchanged.
Why it matters — IMCC watchers would care because the share consolidation changes the share price and count structure of the company's stock on Nasdaq, which could affect how the stock is valued and traded.
IM Cannabis Corp. announced that its board approved a 30:1 consolidation of its common shares, with an expected effective date of August 27, 2026, to help the company meet Nasdaq's minimum bid price requirement.
Why it matters — The share consolidation is a corporate action aimed at supporting IMCC's continued Nasdaq listing compliance, which watchers would track for its potential impact on the stock's trading structure.
IM Cannabis Corp. agreed on Monday to divest its subsidiary IMC Holdings Ltd. to Slil.com Holding Ltd. as part of a restructuring deal aimed at reducing financial strain.
Why it matters — IMCC watchers would care because this divestiture is part of a restructuring effort intended to ease the company's financial burden.
IM Cannabis Corp. announced it has entered into a definitive share purchase agreement dated August 16, 2026, with Slil.com Holding Ltd. and I.M.C. to sell IMC Holdings and its European-focused assets. The transaction is expected to improve shareholders' equity by approximately CAD$3 million.
Why it matters — This divestiture of European assets could reshape IMCC's business structure and improve its shareholders' equity position.
Of the 1 analysts covering IM Cannabis Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IM Cannabis Corp. 29 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, IM Cannabis Corp. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
No analyst covering IM Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMCC are extrapolating price history, which says nothing about the business.
IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany.
The most recent item we track (PRNewsWire, 2 Sept 2026): "IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing". IM Cannabis Corp. announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor, according to a Sept. 2, 2026 press release from Toronto and Glil Yam, Israel.
IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany. The company offers dried flower and full-spectrum cannabis extract products under brands including IMC, BLKMT, and LOT420, with a business model centered on regulated medical markets and pharmacy-based supply chains. Its operations include product sourcing, quality control, and market-specific distribution across Europe and the Middle East, supporting physicians, pharmacies, and patients who rely on standardized cannabis formulations. IM Cannabis Corp. also maintains an online and retail presence tied to its medical cannabis ecosystem, reinforcing its role as a specialized supplier within the healthcare and life sciences sectors. Headquartered in Kibbutz Glil-Yam, Israel, the company remains positioned as a focused participant in the growing regulated medical cannabis market.
CEO Mr. Oren Shuster · 44 employees · Canada · https://imcannabis.com